methotrexate
methotrexate: 77 clinical trials tracked.
methotrexate evidence translation
What we can confirm
77 tracked trials
What it means
What to watch
Prepared research question
What is verified about methotrexate, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 24 study sponsors
Related indications
Clinical Trials (77)showing 10 most recent
A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) With Persistent Measurable Residual Disease (MRD)
Primary endpoint: Dose limiting toxicities (Safety run-in: Cohort A)
A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)
Primary endpoint: Event-free survival (EFS) in patients with newly diagnosed T-cell lymphoblastic leukemia (T-ALL)
Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With Methotrexate for the Treatment of Rheumatoid Arthritis
Primary endpoint: ACR 20 response
Open-label, Phase I/II Study to Evaluate Safety and Efficacy of Asciminib With Chemotherapy Followed by Asciminib Plus Blinatumomab in Pediatric, Adolescent, and Young Adults With Relapsed or Refractory BCR::ABL1-positive (Philadelphia Positive, Ph+) or BCR::ABL1-like (Ph-like) ALL
Primary endpoint: Part 1 Dose Escalation: Incidence of Dose Limiting Toxicities (DLTs) occurring during cycle 1 (debulking induction)
Treatment Strategy for Patients With Rheumatoid Arthritis Associated Interstitial Lung Disease
Primary endpoint: Change in FVC from baseline to week 52
A Phase II Open Label Basket Trial Study Using Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Primary endpoint: Number of Cohort 1 participants with relapse free survival (RFS) during study
A Phase 4 Study of Immune Modulation During Palynziq® Treatment in Adults With Phenylketonuria (PKU)
Primary endpoint: Change in blood Phe levels from baseline to Week 25 and Week 49
A Phase 3, Multicenter, Double-blind, Randomized Controlled Study Evaluating the Efficacy and Safety of Pegloticase Administered by Subcutaneous Injection Compared With Pegloticase Administered by Intravenous Injection, Both Administered Concurrently With Methotrexate Weekly, in Participants With Uncontrolled Gout
Primary endpoint: Number of Participants Achieving Month 6 Response at Weeks 20, 21, 22, 23, and 24
A Multicenter, Open-Label, Single-Arm, Prospective Clinical Study of PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) in the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma (ND-PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL)
Primary endpoint: 1 year Progression free survival (PFS)
Peri-Hematopoietic Cell Transplantation Ruxolitinib in Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Primary endpoint: Incidence of grade II-IV graft versus host disease (GVHD) requiring systemic immune suppression